Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Reaching the Undiagnosed

Babafemi Taiwo, MBBS
Program Director
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Released: September 1, 2022

Information on this Educational Activity

Program Director

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief,
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS: consultant/advisor/speaker: GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, ViiV.

Faculty

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD

Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town,
Cape Town, South Africa

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD: consultant/advisor/speaker: Cepheid, Gilead, Janssen (Johnson & Johnson), Merck (MSD), ViiV.
Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD

Chief & Director
VHS-Infectious Diseases Medical Centre
Director
Chennai Antiviral Research and Treatment (CART) Clinical Research Site
Voluntary Health Services
Chennai, India

Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD, has no relevant financial relationships to disclose.
Chloe Orkin, MBChB, FRCP, MD

Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD: consultant/advisor/speaker: Gilead, Janssen, MSD, ViiV; researcher: Gilead, Janssen, MSD, ViiV.

Staff

Sarah Anderson, PharmD
Scientific Director
Sarah Anderson, PharmD: previous stock ownership: Merck.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant financial relationships to disclose.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant financial relationships to disclose.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant financial relationships to disclose.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant financial relationships to disclose.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant financial relationships to disclose.

Target Audience

This program is intended for physicians, pharmacists, and other healthcare professionals who provide care for patients with HIV infection.

Goal

The goal of this activity is to improve learners’ competence in deploying strategies to address key gaps in HIV diagnosis and treatment and contribute to progress toward ending the HIV epidemic.

Program Medium

This program has been made available online.

Related Content

Dr Neha Pandit discusses barriers and solutions to PrEP uptake in key patient populations in this commentary from Clinical Care Options (CCO)

person default Neha Pandit, PharmD, AAHIVP, BCPS Released: December 2, 2022

Dr Monica Gandhi discusses key advances in HIV treatment over the past year, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 2, 2022

A patient advocate discusses the importance of community-led HIV treatment and prevention, from Clinical Care Options (CCO)

person default Rena Janamnuaysook, MBA Released: December 2, 2022

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Released: November 30, 2022

Video Chapters


Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings